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ABSTRACT
Background: The International Trauma Questionnaire (ITQ) is a validated measure that 
assesses ICD-11 posttraumatic stress disorder (PTSD) and complex PTSD (CPTSD). An important 
task is to determine whether the ITQ is an appropriate evaluative measure for clinical trials.
Objective: To assess the psychometric properties of the ITQ in the context of treatment and 
determine if the ITQ measures reliable and clinically significant change over the course of 
a psychosocial intervention.
Method: Analyses were based on data from an online skills training programme delivered to 
254 U.S. Veterans. Reliability and validity of the ITQ scores were assessed at baseline. Changes 
in symptom scores and probable diagnostic rates were compared at pre-, mid- and post- 
treatment. A reliable change index (RCI) score was computed to classify participants as 
improved, unchanged, or worsened. The PCL-5 was used as a comparison measure.
Results: Baseline concurrent and factorial validity was similar to previous studies. Internal 
consistency at each assessment was excellent and comparable to the PCL-5. Decline in 
symptoms from pre-to-post-treatment was significant for PTSD and CPTSD symptom profiles. 
Rate of probable disorder (PTSD or CPTSD) declined significantly from pre-treatment to post- 
treatment. Pre-to-post treatment declines exceeded the critical RCI values for the ITQ. Clinically 
significant changes were observed where most participants improved, some stayed the same, 
and few worsened. The performance of the ITQ was consistent with the PCL-5 regarding 
sensitivity to change.
Conclusion: This study provides the first demonstration that the ITQ measures reliable and 
clinically significant treatment-related change of ICD-11 PTSD and CPTSD symptoms.
El Cuestionario Internacional de Trauma (ITQ) mide el cambio 
relacionado con el tratamiento en el TEPT y el TEPT complejo de manera 
confiable y clínicamente significativa
Antecedentes: el Cuestionario Internacional de Trauma (ITQ por su sigla en inglés) es una 
medida validada que evalúa el trastorno por estrés postraumático (TEPT) y el TEPT complejo 
(TEPT-C) según la CIE-11. Una tarea importante es determinar si la ITQ es una medida de 
evaluación adecuada para los ensayos clínicos.
Objetivo: Evaluar las propiedades psicométricas de la ITQ en el contexto del tratamiento 
y determinar si la ITQ mide un cambio confiable y clínicamente significativo durante el 
transcurso de una intervención psicosocial.
Método: Los análisis se basaron en datos de un programa de entrenamiento de habilidades en 
línea entregado a 254 veteranos estadounidenses. La confiabilidad y la validez de las puntua-
ciones de ITQ se evaluaron al inicio del estudio. Se compararon los cambios en las puntuacio-
nes de los síntomas y las tasas de diagnóstico probables antes, en la mitad y después del 
tratamiento. Se calculó una puntuación de índice de cambio confiable (RCI) para clasificar a los 
participantes como mejorados, sin cambios o empeorados. El PCL-5 se utilizó como medida de 
comparación.
Resultados: La validez basal concurrente y factorial fue similar a estudios previos. La consis-
tencia interna en cada evaluación fue excelente y comparable a la del PCL-5. La disminución de 
los síntomas de antes a después del tratamiento fue significativa para los perfiles de síntomas 
de TEPT TEPT-C. La tasa de trastorno probable (TEPT o TEPT-C) disminuyó significativamente 
desde el pretratamiento hasta el postratamiento. Las disminuciones antes-después del trata-
miento excedieron los valores críticos de RCI para la ITQ. Se observaron cambios clínicamente 
significativos en los que la mayoría de los participantes mejoraron, algunos permanecieron 
igual y pocos empeoraron. El desempeño de la ITQ fue consistente con el PCL-5 con respecto 
a la sensibilidad al cambio.
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• This study provides the first 
demonstration that the 
International Trauma 
Questionnaire (ITQ) mea-
sures reliable and clinically 
significant treatment- 
related change in ICD-11 
PTSD and Complex PTSD.  
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Conclusión: Este estudio proporciona la primera demostración de que la ITQ mide cambios 
confiables y clínicamente significativos relacionados con el tratamiento de los síntomas de 
TEPT y TEPT-C de la CIE-11.
国际创伤问卷 (ITQ) 测量了PTSD和复杂性PTSD中可靠且临床显著的治疗 
相关变化
背景: 国际创伤问卷 (ITQ) 是一个经过验证的评估ICD-11创伤后应激障碍 (PTSD) 和复杂性 
PTSD (CPTSD) 的测量工具° 一项重要的任务是确定ITQ是否适合用于临床试验° 目的: 在治疗的背景下评估ITQ的心理测量特性, 并确定ITQ是否测量出可靠且具有临床意义 
的社会心理干预过程中的变化° 方法: 分析基于来自一项提供给254名美国退伍军人的在线技能培训计划的数据° 在基线时评 
估了ITQ得分的信度和效度° 在治疗前, 中, 后比较症状得分的变化和可能的诊断率° 计算了一 
个可靠的变化指数 (RCI) 分数, 以将参与者分为改善, 不变或恶化°  PCL-5用作对比测量° 结果: 基线的同时和因素效度与前人研究相似° 每次评估的内部一致性都非常好, 可与PCL-5 
相媲美° 对于PTSD和CPTSD症状, 治疗前后症状的下降是显著的° 从治疗前到治疗后, 可能的 
发病率 (PTSD或CPTSD) 显著下降° 治疗前后下降幅度超过了ITQ的关键RCI值° 观察到了临床 
上显著的变化, 大多数参与者有所改善, 一些参与者保持不变, 很少恶化°  ITQ在对改变的敏感 
性上的表现与PCL-5一致° 结论: 本研究首次证明了ITQ可测量ICD-11 PTSD和CPTSD症状的可靠且临床显著的治疗相关 
变化° 
The 11th edition of the International Classification of 
Disorders and Related Health Problems (ICD-11; 
World Health Organization, 2018) brought significant 
changes to the formulation of posttraumatic stress dis-
order (PTSD) and introduced a new disorder, complex 
PTSD (CPTSD). The diagnosis of PTSD was refined to 
include symptoms organized into three clusters: re- 
experiencing of the traumatic event in the here and 
now, avoidance of traumatic reminders, and a sense of 
current threat. CPTSD was introduced to describe 
a broader array of symptoms which include not only 
PTSD symptoms but also the adverse effects that 
trauma can have on self-organization, particularly 
when the traumatic experience is of a prolonged or 
repeated nature (e.g. childhood abuse, domestic vio-
lence). The diagnosis of CPTSD is comprised of six 
symptom clusters; the three PTSD clusters and three 
clusters related to disturbances in self-organization 
(DSO): affect dysregulation, negative self-concept, and 
disturbances in relationships (Maercker et al., 2013).
Clinical interviews and self-report instruments for 
assessing ICD-11 PTSD and CPTSD have been devel-
oped to align with ICD-11 criteria (e.g. Litvin, 
Kaminski, & Riggs, 2017; Roberts, Cloitre, Bisson, & 
Brewin, 2018). One of the more widely used self- 
report questionnaires is the International Trauma 
Questionnaire (ITQ: Cloitre et al., 2018). 
Psychometric evaluations indicate that the PTSD and 
DSO items of the ITQ produce scores with satisfactory 
internal consistency, as measured by Cronbach’s alpha 
(α), across a range of study samples including epide-
miological (Ben-Ezra et al., 2018; Cloitre et al., 2019), 
community (Ho et al., 2020, 2019), and clinical 
(Hyland, Shevlin, Fyvie, & Karatzias, 2018; 
Kazlauskas, Gegieckaite, Hyland, Zelviene, & Cloitre, 
2018) samples as well as among refugees (Hyland 
et al., 2018) and military personnel (Letica-Crepulja 
et al., 2020; Mordeno, Nalipay, & Mordeno, 2019; 
Murphy et al., 2020).
Evidence of the concurrent and discriminant valid-
ity of the ITQ scores has been demonstrated in studies 
showing that the PTSD and DSO item clusters are 
differentially related to multiple criterion variables 
(e.g. Ho et al., 2019; Hyland et al., 2017). For example, 
Hyland et al. (2017) reported that the PTSD symptoms 
uniquely predicted panic disorder symptoms and were 
a stronger predictor of anxiety symptoms relative to 
the DSO symptoms, whereas DSO symptoms pre-
dicted emotion dysregulation, negative beliefs about 
self, negative beliefs about the world, and depression 
while the PTSD symptoms did not. Discriminant 
validity has also been demonstrated in studies using 
latent profile analyses and latent class analyses of 
trauma samples. Consistent with the proposed distinc-
tion between the diagnosis of PTSD and CPTSD, 
analyses of study samples have consistently revealed 
two subgroups distinguished by different patterns of 
symptom endorsement, one following the PTSD pro-
file and the other following the CPTSD profile (e.g. 
Karatzias et al., 2017; Kazlauskas et al., 2018; Murphy, 
Elklit, Dokkedahl, & Shevlin, 2016). A recent systema-
tic review of factor analytic and latent class/profile 
analyses with the ITQ reported that, across a total of 
12 studies, the number of profiles identified varied 
from two to six; however, all analyses evidenced 
a PTSD and a CPTSD profile (Redican et al., 2021).
Lastly, the factorial validity of the ITQ has also been 
demonstrated across different countries and cultures 
(Redican et al., 2021). Two models have consistently 
been found to fit the data well (Shevlin et al., 2017). 
The first is a correlated six-factor model (e.g. Ben-Ezra 
et al., 2018; Ho et al., 2020; Mordeno et al., 2019), and 
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the second is a two-factor, higher order model in 
which the three PTSD symptom clusters fall under 
a PTSD factor and the three DSO clusters fall under 
a DSO factor (e.g. Hyland et al., 2017; Karatzias et al., 
2016; Kazlauskas et al., 2018; Owczarek et al., 2020; 
Vallières et al., 2018). The review found that the two- 
factor second-order solution was the best fit in the 
majority but not all clinical studies while community 
setting studies were equally split between finding the 
first order versus the two-factor model as the better fit. 
Notably, all studies tested both models and all found 
that both were a good fit to the data (Redican et al., 
2021).
An important next step is to determine whether the 
ITQ is responsive to change and appropriate as an 
evaluative measure for clinical trials (Guyatt, 
Kirshner, & Jaeschke, 1992). A measure’s responsive-
ness to change is sometimes seen as a form of validity 
(Hays & Hadorn, 1992), and other times as 
a psychometric characteristic separate from reliability 
and validity (Guyatt, Walter, & Norman, 1987). 
Regardless of its psychometric placement, an evalua-
tive measure must be sufficiently sensitive to capture 
real change over time. In clinical research, reliable and 
clinically significant change is often used to summar-
ize responsiveness at the individual level within the 
context of observed reliable changes for the whole 
group (Evans, Margison, & Barkham, 1998). To date, 
no study has evaluated the psychometric properties of 
the ITQ during treatment.
The study had two objectives. The first objective 
was to replicate findings of the concurrent, discrimi-
nant, and factorial validity, as well as the internal 
consistency, of the ITQ scores in a treatment context. 
The second and more important goal was to deter-
mine the ability of the ITQ to measure reliable and 
clinically significant change in symptoms scores, and 
probable diagnostic status, over the course of 
a psychological intervention. Because the PTSD 
Checklist for DSM-5 (PCL-5; Weathers et al., 2013) 
is a frequently used self-report measure in PTSD out-
come studies, we included the PCL-5 as an external 
comparator.
This study utilized data from a web-based psycho-
social transdiagnostic intervention (webSTAIR) eva-
luation programme delivered to U.S. Veterans, one 
goal of which was to increase engagement into care 
among trauma-exposed Veterans via the use of tech-
nology as well as via the application of a relatively 
‘wide net’ inclusion criteria. Accordingly, enrollment 
into the programme required a positive screen for 
either PTSD or depression. This enrollment strategy 
was based on literature indicating that PTSD and 
depression are highly comorbid (Rytwinski, Scur, 
Feeny, & Youngstrom, 2013), particularly among 
Veterans (Chan, Cheadle, Reiber, Unützer, & 
Chaney, 2009) and that emotion regulation and 
interpersonal difficulties, key targets in the 
webSTAIR intervention, are associated with both 
depression and PTSD (Beck, Grant, Clapp, & Palyo, 
2009; Cloitre, Hyland et al., 2019). The use of data 
from the evaluation programme was appropriate for 
the goals of this psychometric study as we surmised 
that the ‘wide net’ inclusion criteria would yield 
enrollment of individuals with ICD-11 PTSD as 
well as those with CPTSD.
1. Methods
1.1. Participants and procedure
Participants were 254 male and female United States 
(U.S.) Veterans enrolled in an online 10-module web- 
based (i.e. webSTAIR) programme recruited from 
eight, predominantly rural Veterans Affairs facilities 
located across the country. Enrolment into the pro-
gramme was based on referrals by mental health pro-
viders. The study combined data from three different 
evaluation projects that varied by amount of coaching 
support provided to the Veteran during the 
programme.
Pre-screening criteria included age of 18 years or 
older, history of trauma exposure, positive screen for 
either PTSD symptoms (PC-PTSD-5; Prins et al., 
2016) or depression (PHQ-2; Arroll et al., 2010), no 
changes to medication in the previous 6 weeks, will-
ingness to use an online treatment format and avail-
ability for the duration of the study. Exclusion 
criteria included presence of psychosis and signifi-
cant cognitive impairment as assessed by the evalua-
tor during the screen. Participants were required to 
complete the 10 modules over a 15-week period. 
Assessment data included in this study were collected 
at pre-treatment, preceding entry into the first mod-
ule (T1, n = 254), mid-treatment, following the com-
pletion of the fifth module (T2, n = 168, follow-up 
rate = 66.1%), and post-treatment, following comple-
tion of the tenth module (T3, n = 130, follow-up 
rate = 51.2%). Non-completers were significantly 
younger than completers (M = 42.80 vs M = 46.25, 
t(254) = 2.34, p = .021). On all other demographic, 
symptomatic, and diagnostic variables, there were no 
significant differences between completers and non- 
completers.
Assessments were completed via phone guided by 
a Master’s level psychologist. Participants received 
copies of all measures via mail and used the forms to 
report their scores. Participants were paid 30.00 USD, 
for each assessment. This study was approved by the 
study site’s VA Research and Development 
Committee. The Institutional Review Board affiliated 
with the VA approved the study and a waiver of 
informed consent was provided as the project was 
considered an evaluation project and not research.
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1.2. Intervention
The webSTAIR programme consists of 10 web-based 
modules adapted from STAIR (Bauer et al., 2021; 
Cloitre, Cohen, Ortigo, Jackson, & Koenen, 2020). 
The first five modules review emotional awareness, 
emotion management, and distress tolerance, while 
the final five modules raise awareness about relation-
ship patterns and provide interpersonal skills training 
regarding effective assertiveness, interpersonal flexibil-
ity, and compassion for self and others. The primary 
goal of webSTAIR, identical to STAIR, is to improve 
functioning via increased emotion regulation and 
interpersonal skills. Nevertheless, data from recent 
treatment outcome studies indicates that STAIR is 
effective in providing significant reductions in DSM- 
5 PTSD and depression among veterans receiving 
mental health services in primary care (Jain et al., 
2020), PTSD speciality care (Jackson, Weiss, & 
Cloitre, 2019) and telemental health for military sexual 
trauma (Weiss, Azevedo, Webb, Gimeno, & Cloitre, 
2018) as well as in receipt of the web-based version of 
STAIR (Bauer et al., 2021).
1.3. Measures
The International Trauma Questionnaire (ITQ: 
Cloitre et al., 2018) was used to measure PTSD and 
CPTSD symptoms at the three assessment periods. 
The ITQ first screens for a respondent’s ‘index’ trauma 
event and participants are instructed to answer all 
questions in relation to this event. The ITQ includes 
six items measuring each PTSD symptom from the 
three clusters of ‘Re-experiencing in the here and 
now’, ‘Avoidance’, and ‘Sense of Threat’, and these 
items are answered in terms of how bothersome that 
symptom has been in the past month. The ITQ also 
includes six items measuring each ‘Disturbance in 
Self-Organization’ (DSO) symptom from the three 
clusters of ‘Affective Dysregulation’, ‘Negative Self- 
Concept’, and ‘Disturbed Relationships’. These items 
are answered in terms of how a respondent typically 
feels, thinks about oneself, and relates to others. The 
PTSD and DSO symptoms are accompanied by three 
items measuring associated functional impairments in 
the domains of social, occupation, and other impor-
tant areas of life.
All ITQ items are answered on a 5-point Likert 
scale ranging from 0 (Not at all) to 4 (Extremely). 
Thus, PTSD and DSO symptom scores range from 0 
to 24 (i.e. the sum of the six items from each sub-
scale), and CPTSD symptom scores range from 0 to 
48 (i.e. the sum of the 12 ITQ items). For diagnostic 
purposes, each symptom and functional impairment 
indicator was considered ‘present’ based on a score 
of ≥ 2 (Moderately) on the Likert scale (Cloitre et al., 
2018). The requirements for probable PTSD 
diagnosis are met if a person is trauma exposed, at 
least one symptom is present from each PTSD clus-
ter, and there is functional impairment associated 
with these symptoms. The diagnostic requirements 
for CPTSD are met if the PTSD criteria are satisfied, 
and at least one symptom is present from each DSO 
cluster, and there is functional impairment asso-
ciated with these symptoms. As per the ICD-11 
diagnostic rules, a person can may receive 
a diagnosis of PTSD or CPTSD, but not both. 
Thus, if a person meets the criteria for CPTSD they 
do not also receive a diagnosis of PTSD. In this 
study, we examine changes in (a) probable PTSD 
diagnostic rates, (b) probable CPTSD diagnostic 
rates, and (c) probable PTSD or CPTSD diagnostic 
rates (i.e. the total number of PTSD and CPTSD 
cases).
The following measures were used to explore dif-
ferential associations with the ITQ PTSD and DSO 
subscales. The PCL-5 was also used as a comparator 
measure of change across assessments. The PCL-5 is 
a frequently used treatment outcome measure in 
PTSD trails and is similar to the ITQ in that respon-
dents rate the degree to which they have been ‘both-
ered’ by symptoms (0 = not at all to 4 = extremely) in 
the past month.
1.3.1. PTSD Checklist for DSM-5 (PCL-5; Weathers 
et al., 2013)
The PCL-5 is a 20-item self-report measure of PTSD as 
assessed in the DSM-5. It is comprised of four symp-
tom clusters: intrusions (5 items), avoidance (2 items), 
negative alterations in cognitions and mood (7 items) 
and alterations in arousal and reactivity (6 items). 
Responses are summed to create a total score, with 
higher scores indicating more severe PTSD symptoms. 
The PCL-5 has good psychometric properties in 
veteran samples and has demonstrated sensitivity to 
clinical change pre to post treatment (Bovin et al., 
2016; Wortmann et al., 2016).
Difficulties in Emotion Regulation Scale (DERS; 
Gratz & Roemer, 2004) was used to measure emotion 
regulation. The DERS is 36-item measure which asks 
participants to rate items on a scale of 0 (almost never) 
to 5 (almost always) identifying how often a person 
experiences difficulties in emotion regulation. 
Responses were summed to create a total score with 
higher scores indicating greater emotion regulation 
difficulties.
Inventory of Interpersonal Problems 32 item Version 
(IIP-32, Barkham, Hardy, & Startup, 1996) was used to 
measure interpersonal difficulties. The IIP-32 is a 32- 
item self-report measure which asks participants to 
rate difficulties with someone important in their life 
on a scale of 0 (not at all) to 4 (extremely). Responses 
were averaged to create a mean score, with higher 
scores indicating greater interpersonal difficulties.
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1.4. Data analytic plan and predictions
1.4.1. Phase 1: examination of concurrent, 
discriminant, factorial validity and internal 
consistency of the ITQ scores
Baseline zero-order correlations were computed for 
all measures to identify differential correlations 
between the ITQ subscales and the various other 
measures outlined above. It was expected that obser-
vation of the pattern of correlations would find that 
the largest correlations for the ITQ PTSD subscale 
would be with the PCL-5 intrusions, avoidance, and 
arousal clusters while the correlations with the DERS 
and IIP-32 would be smaller. We also expected that 
the largest correlations for the ITQ DSO cluster 
would be with the DERS and IIP-32 while those 
with the PCL-5 intrusion, avoidance, and arousal 
clusters would be smaller. The webSTAIR interven-
tion study did not include a measure of self-concept 
and so assessment of the concurrent validity of the 
ITQ in regard to this construct could not be 
evaluated.
Factorial validity was tested via confirmatory factor 
analysis on the data at baseline. The two models sup-
ported in the literature (Redican et al., 2021) – the 
correlated six-factor model and the two-factor second- 
order model – were assessed. The models were tested 
using Weighted Least-Squares Mean and Variance 
(WLSMV) adjusted estimation, and model fit was 
judge in relation to standard recommendations (Hu 
& Bentler, 1999). It was predicted that both models 
would fit the data well but the two-factor second-order 
model might be a closer fit of the data (see Redican 
et al., 2021).
Cronbach’s alpha was computed for the ITQ, as 
well as the PCL-5, DERS and IIP-32, for purposes of 
comparison at each assessment point (pre, mid, and 
post treatment). It was expected that the internal con-
sistency of the ITQ would high, stable across time, and 
comparable to those of more established measures.
1.4.2. Phase 2: testing for change
The second phase involved testing for change in (a) 
symptom scores (i.e. PTSD symptoms, DSO symp-
toms, and CPTSD symptoms), and (b) probable diag-
nostic rates (i.e. PTSD, CPTSD, and PTSD or CPTSD) 
across the three assessments. A repeated measures 
ANOVA would be unsatisfactory to test for such 
changes as it makes strong assumptions about the 
data such as sphericity (Hancock & Mueller, 2013), 
and relies on listwise deletion to handle missing obser-
vations. The repeated measures ANOVA can, how-
ever, be specified as a more general model within 
a structural equation modelling framework where no 
assumptions are made about the variance–covariance 
structure of the observations (Hoffman, 2015) and 
missing data are handled efficiently using full 
information maximum likelihood estimation (MLR: 
Schafer & Graham, 2002).
This analytic process involves several steps. 
Initially, for each variable (e.g. symptoms of PTSD, 
DSO, and CPTSD and diagnostic status), a null or 
‘constrained’ model was specified where the three 
means were constrained equal. Next, an alternative 
or ‘unconstrained’ model was specified with the three 
means freely estimated. The constrained and uncon-
strained models differed by two degrees of freedom so 
improvement in model fit can be tested using the 
loglikelihood difference test, which is distributed as 
a chi-square (χ2). A significant χ2 result indicates that 
the unconstrained model is better than the con-
strained model, meaning that the null hypothesis of 
equal means can be rejected (Hoffman, 2015). 
Importantly, the use of MLR estimation means that 
all available information at T1 (n = 240) was used to 
estimate the means, variances, and covariances at T2 
and T3, thus avoiding the deleterious effects of listwise 
deletion.
These models were specified and estimated using 
Mplus Version 8.2 (Muthén & Muthén, 2018). Mplus 
also incorporates the ‘model test’ feature that allows 
constraints to be tested using the Wald χ2 test, and this 
was used to test pairwise comparisons (T1 vs T2, T2 vs 
T3, and T1 vs T3). The magnitude of the change in 
symptoms scores was then calculated using Cohen’s 
d with a correction for repeated measures designs 
(drm). Values < 0.40 reflect ‘small’ effects, values 
from 0.40 to 0.79 reflect ‘medium’ effects, and values 
≥ 0.80 reflect ‘large’ effects (Fritz, Morris, & Richler, 
2011). This approach was also used to test for the 
equality of proportions (i.e. changes probable diagnos-
tic rates of PTSD, CPTSD, and PTSD or CPTSD) 
across the three assessment periods.
1.4.3. Phase three: testing for reliable and ‘clinically 
significant’ change
The third phase of the analyses focused on testing if 
the ITQ scores captured reliable and ‘clinically signifi-
cant’ change over time. To do so, the approach pro-
posed by Jacobson and Truax (1991) was followed and 
a Reliable Change Index (RCI) value was calculated for 
PTSD symptoms, DSO symptoms, and CPTSD symp-
toms as well as for the PCL-5. The RCI reflects the 
change in symptoms from pre-treatment (T1) to post- 
treatment (T3) that cannot be attributed to measure-
ment error. In other words, the RCI reflects the abso-
lute change in scores on the ITQ that must occur to be 
confident that the observed change was not due to 
random fluctuations over time (at a probability level 
of < 5%). The RCI is calculated by dividing the differ-
ence between the pre-treatment and post-treatment 
scores by the standard error of the difference between 
these two scores. The standard error of the difference 
in the scores is determined using the standard 
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deviation and internal reliability estimates of the scale 
scores from the pre-treatment assessment period 
(Ferguson, Robinson, & Splaine, 2002). We used 
a freely available online calculator to calculate the 
RCI values for the ITQ and the PCL-5 (https://www. 
psyctc.org/stats/rcsc1.htm).
To determine if the observed change in symptom 
scores were ‘clinically significant’, Jacobson and Truax 
(1991) recommend comparing the RCI from 
a ‘treatment’ group to a ‘normative’ population 
group. As there are no population norms available 
for the ITQ (it is only used with trauma-exposed 
persons), we followed the approach suggested by 
Shiner, Watts, Pomerantz, Young-Xu, and Schnurr 
(2011) for measures of trauma-related symptoms. 
We used the critical RCI values determined in the 
previous step to classify participants as ‘improved’ 
(i.e. a decrease in symptom scores for PTSD, DSO, 
and CPTSD that exceed the relevant RCI values), 
‘worsened’ (i.e. an increase in symptom scores for 
PTSD, DSO, and CPTSD that exceed the relevant 
RCI values), or ‘unchanged’ (i.e. a change in symptom 
scores for PTSD, DSO, and CPTSD that does not 
exceed the relevant RCI values in either direction). 
These analyses were repeated for the PCL-5 scores as 
a comparator measure of change across assessments.
2. Results
2.1. Participants
The sample had a mean age of 44.20 (Mdn = 43.00, 
SD = 11.94, range: 22–77); 61.8% identified as female, 
37.6% identified as male, and 0.6% as other (e.g. trans-
gender). In terms of racial/ethnic background, 63.9% 
identified as White/Caucasian, 17.5% identified as 
Black/African American, 5.6% identified as Hispanic/ 
Latino(a)/Mexican American, 1.9% identified as 
American Indian/Alaskan Native, 1.5% as Asian, and 
4.5% identified as Other. In terms of education, 53.2% 
had completed some college/2 year degree, 23.6% had 
completed a 4-year college degree, 10.2% had com-
pleted a postgraduate degree, 12.1% earned a high 
school degree, and 1.0% had completed some high 
school. Most participants stated that they were 
employed full or part time (42.2%), 34.8% were unem-
ployed, and 23.0% were retired. Regarding relation-
ship status, 55.1% reported being married/partnered, 
20.9% as single, 23.3% as divorced, and 1% as 
widowed. Participants served in a variety of conflict 
eras, with 11.1% serving during the Vietnam war, 
25.8% during the Persian Gulf War, 35.9% during 
the Iraq and Afghanistan conflicts, and 26.2% in 
some other conflict. More than half of the sample 
(51.7%) reported being deployed during service.
The sample had experienced multiple and chronic 
forms of trauma exposure. The average number of 
traumatic life events reported was 7.80 (SD = 3.05). 
The three most frequently endorsed events were (1) 
sudden unexpected death of a loved one (81.4%), (2) 
physical assault (75.5%), and (3) transportation acci-
dent (75.9%). A total of 53% reported combat experi-
ence, 34% reported childhood sexual abuse and 47% 
reported childhood physical abuse.
2.2. Baseline concurrent validity
Table 1 provides the baseline zero order correlations 
among the ITQ and its subscales, the PCL-5 and its 
subscales, the DERS, and the IIP-32. Consistent with 
expectations, a review of the pattern of associations 
indicates that the largest correlations for the ITQ 
PTSD subscale were with PCL-5 intrusions (r = .86), 
avoidance (r = .75) and arousal (r = .75), while those 
related to the DERS (r = .49) and the IIP-32 (r = .47) 
were smaller. Conversely, the largest correlations for 
the ITQ DSO subscales were the DERS (r = .71) and 
the IIP-32 (r = .63) with smaller correlations asso-
ciated with PCL-5 intrusion (r = .58), avoidance 
(r = .50), and arousal (r = .59).
2.3. Baseline factorial validity and internal 
reliability
The two-factor second-order model (χ2 (47) = 80.57, 
p = .002; CFI = .98; TLI = .97; RMSEA = .05 (.03, .07); 
SRMR = .04) and the correlated six-factor model (χ2 
Table 1. Correlations among variables at baseline.
1 2 3 4 5 6 7 8 9 10
1. Total ITQ 1
2. ITQ-PTSD .84*** 1
3. ITQ-DSO .85*** .56** 1
4. Total PCL-5 .89*** .87*** .72*** 1
5. PCL5-Intrusions .79*** .86*** .58*** .87*** 1
6. PCL5-Avoidance .69*** .75*** .50*** .77*** .69*** 1
7. PCL5-NACM .81*** .65*** .76*** .87*** .64*** .61*** 1
8. PCL5-Arousal .76*** .75*** .59*** .85*** .67*** .56*** .63*** 1
9. Total DERS .66*** .49*** .71*** .59*** .48*** .39*** .58*** .54*** 1
10. Total IIP-32 .64*** .47*** .63*** .58*** .46*** .39*** .57*** .51*** .62*** 1
Statistical significance: *p < .05; **p < .01; ***p < .001. 
ITQ = International Trauma Questionnaire; PTSD = Posttraumatic Stress Disorder; DSO = Disturbances in Self-Organization; PCL-5 = Posttraumatic Stress 
Disorder Checklist for DSM-5; NAMC = Negative Alterations in Cognitions and Mood; DERS = Difficulties in Emotion Regulation Scale; IIP-32 = Inventory of 
Interpersonal Problems- 32 Item Version.
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(39) = 67.12, p = .003; CFI = .98; TLI = .97; 
RMSEA = .05 (.031, .074); SRMR = .03) were both 
good fitting models and were statistically indistin-
guishable from one another. The second-order 
model may be preferred based on parsimony.
Table 2 provides the Cronbach’s alpha for all mea-
sures as well as the associated mean and standard 
deviations at pre-, mid- and post-treatment. Alphas 
for the ITQ were high ranging from .89 to .94 and 
stable over time. Alphas for the ITQ were comparable 
to those for the PCL-5 which ranged from .92 to .96 as 
well as to those for the DERS and IIP-32 which ranged 
from .85 to .95.
2.4. Change in symptoms over time
The means and standard deviations for the PTSD, 
DSO, and CPTSD symptom scores at each assessment, 
along with the overall and pairwise χ2 test results, are 
presented in Table 3. In every case, the ‘unconstrained’ 
model was significantly (ps < .001) different from the 
‘constrained’ model indicating that the mean scores 
for PTSD, DSO, and CPTSD significantly changed 
across the three assessments. All pairwise comparisons 
were statistically significant (ps < .001), and inspection 
of the means showed that PTSD, DSO, and CPTSD 
symptoms significantly declined through each assess-
ment. The magnitude of the decline in PTSD symp-
toms from pre-treatment to post-treatment was 
‘moderate’ (Cohen’s drm = 0.71), and the decline in 
DSO symptoms (Cohen’s drm = 0.86) and CPTSD 
symptoms (Cohen’s drm = 0.94) from pre-treatment 
to post-treatment were ‘large’. Similar results were 
obtained for the PCL-5 where symptoms significantly 
declined through each assessment, and the magnitude 
of change was large (Cohen’s drm = 0.96).
2.5. Change in probable diagnostic rates over 
time
The probable diagnostic rates for PTSD, CPTSD, and 
PTSD or CPTSD at each assessment, along with the 
overall and pairwise χ2 test results, are presented in 
Table 4. At pre-treatment (T1), 70.9% of participants 
met requirements for a probable diagnosis of PTSD or 
CPTSD, and there were more people who met require-
ments for CPTSD (52.8%) than PTSD (18.1%).
In all cases the unconstrained models of change in 
probable diagnostic status were statistically different 
from the constrained models indicating that rates of 
PTSD (p < .05), CPTSD (p < .001), and PTSD or 
CPTSD (p < .001) significantly declined across the 
three assessments. The pairwise comparisons for 
PTSD showed no significant change from pre- 
treatment to mid-treatment, or from mid-treatment 
to post-treatment; however, the decline from pre- 
treatment to post-treatment was statistically signifi-
cant. In the case of CPTSD, and PTSD or CPTSD, all 
pairwise comparisons were statistically significant 
indicating that these rates declined through each 
assessment period.
2.6. Reliable and clinically significant change in 
symptoms over time
Based on the means, standard deviations, and internal 
consistency values for the ITQ at baseline, critical RCI 
values were calculated for the ITQ and the PTSD and 
Table 2. Descriptive statistics and cronbach’s alpha for study measures at pre-, mid-, and post-treatment.
Pre-Treatment Mid-Treatment Post-Treatment
Variables Mean (SD) Cronbach’s Alpha Mean (SD) Cronbach’s Alpha Mean (SD) Cronbach’s Alpha
Total ITQ 31.00 (9.75) .89 26.20 (10.66) .92 23.12 (11.92) .94
Total PCL-5 50.59 (15.62) .92 43.49 (17.72) .95 37.93 (19.16) .96
Total DERS 110.11 (25.36) .94 98.76 (23.52) .94 90.89 (25.88) .95
Total IIP-32 58.89 (16.77) .85 55.26 (18.27) .89 49.86 (19.59) .92
ITQ = International Trauma Questionnaire; PCL-5 = Posttraumatic Stress Disorder Checklist for DSM-5; DERS = Difficulties in Emotion Regulation Scale; IIP- 
32 = Inventory of Interpersonal Problems- 32 Item Version.









Time 1: Pre-treatment 15.84 (5.58) 15.15 (5.46) 31.00 (9.75) 50.59 (15.62)
Time 2: Mid-treatment 14.12 (5.77) 12.12 (5.87) 26.20 (10.66) 43.49 (17.72)
Time 3: Post-treatment 12.64 (6.24) 10.51 (6.23) 23.12 (11.92) 37.93 (19.16)
Overall test of significance (χ2)^ 52.82 (p < .001) 83.64 (p < .001) 83.98 (p < .001) 78.35 (p < .001)
Pairwise tests of significance (Wald χ2)^^
Time 1 vs. Time 2, Cohen’s drm 34.96 (p < .001), 0.45 84.45 (p < .001), 0.72 83.39 (p < .001), 0.73 62.21 (p < .001), 0.76
Time 2 vs. Time 3, Cohen’s drm 23.14 (p < .001), 0.47 21.54 (p < .001), 0.42 27.53 (p < .001), 0.51 32.03 (p < .001), 0.48
Time 1 vs. Time 3, Cohen’s drm 62.36 (p < .001), 0.71 100.29 (p < .001), 0.86 101.33 (p < .001), 0.94 100.84 (p < .001), 0.96
^ tests have 2 degrees of freedom; ^^ tests have 1 degree of freedom; Cohen’s drm = Cohen’s d value corrected for repeated measures. 
PTSD = Posttraumatic Stress Disorder; DSO = Disturbances in Self-Organization; CPTSD = Complex PTSD; PCL-5 = Posttraumatic Stress Disorder Checklist 
for DSM-5.
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DSO subscales (see the fourth column of Table 5). The 
decline in CPTSD symptoms scores from pre-treatment 
to post-treatment (7.88) exceeded the critical RCI value 
of 5.41 for the ITQ. Moreover, the pre-treatment to 
post-treatment decline in DSO symptoms (4.64) also 
exceeded the relevant critical RCI values for these sub-
scales. However, the pre-treatment to post-treatment 
decline in PTSD symptoms (3.20) did not. Thus, the 
ITQ measured reliable changes in DSO and CPTSD 
symptoms across the three assessment periods of this 
intervention. The decline in PCL-5 scores from pre- to 
post-treatment (12.66) exceeded the critical RCI of 9.68 
indicating reliable changes in PCL-5 scores.
Table 5 also includes information about the propor-
tion of patients who experienced ‘clinically significant’ 
changes in PTSD, DSO, and CPTSD symptoms from 
pre-treatment to post-treatment. For PTSD symp-
toms, 43.1% of patients ‘improved’, 6.5% ‘worsened’, 
and 50.4% were ‘unchanged’. For DSO symptoms, 
54.0% ‘improved’, 2.4% ‘worsened’, and 43.5% were 
‘unchanged’. Finally, for CPTSD symptoms, 56.1% 
‘improved’, 4.9% ‘worsened’, and 39.0% were 
‘unchanged’. These changes were similar to those 
observed for the PCL-5 where 54.8% of patients 
‘improved’ 2.4% ‘worsened’ and 42.7% unchanged.
3. Discussion
The study was performed to provide a comprehensive 
assessment of the psychometric properties of the ITQ 
scores in the context of a treatment study. Our results 
provided support for the concurrent, discriminant, 
and factorial validity of the ITQ scores, similar to 
previous studies with clinical and non-clinical samples 
(Redican et al., 2021). The internal consistency of the 
ITQ scores across pre-, mid- and post-treatment was 
high and stable across time and comparable to the 
PCL-5, DERS and IIP-32. More importantly, the 
study demonstrated that the ITQ captures reliable 
and clinically significant change during treatment. 
Means and standard deviations of the PTSD, DSO 
and CPTSD scores significantly declined across assess-
ments, as did the probable diagnoses of PTSD and 
CPTSD. Critical RCI values for PTSD symptoms, 
DSO symptoms, and total score (CPTSD) symptoms 
were calculated and change patterns based on the RCI 
were similar to the PCL-5. Overall, the performance of 
the ITQ was consistent with, and similar to that found 
for the PCL-5 in terms of magnitude, reliability, and 
clinical significance of change.
There were significant reductions in the rates of 
ICD-11 PTSD diagnoses from pre to post treatment 
(from 18.1% to 11.0%) and significant and substan-
tial reductions in CPTSD (from 52.8% to 12.6%). 
The decline in symptoms from pre-to-post- 
treatment for the ITQ (Cohen’s drm = .94) and 
PCL-5 (Cohen’s drm = 0.94) total scores were 
large and equivalent. The decline in symptoms for 
the PTSD and DSO subscales differed slightly 
where the changes in symptoms from pre-to-post- 
treatment were moderate for the PTSD scores 
(Cohen’s drm = 0.71) and large for DSO (Cohen’s 
drm = 0.86). Critical RCIs were used to identify 
‘clinically significant change’ where status as 
‘improved’ was defined as a decrease in scores 
that exceeded the relevant RCI values, status as 
‘worsened’ was defined as an increase in scores 
that exceeded the relevant RCI values, and status 
as ‘unchanged’ was defined as a change not exceed-
ing the relevant RCI values in either direction 
Table 5. Reliable change index (RCI) results for the ITQ (n = 254) and clinically significant change results (n = 123).
Reliable 
change?
Clinically significant change 
















PTSD 15.84 12.64 3.20 3.79 N 43.1% 6.5% 50.4%
DSO 15.15 10.51 4.64 4.54 Y 54.0% 2.4% 43.5%
CPTSD 31.00 23.12 7.88 5.41 Y 56.1% 4.9% 39.0%
PCL-5 50.59 37.93 12.66 9.68 Y 54.8% 2.4% 42.7%
PTSD = Posttraumatic Stress Disorder; DSO = Disturbances in Self-Organization; CPTSD = Complex PTSD; PCL-5 = Posttraumatic Stress Disorder Checklist 
for DSM-5.
Table 4. Tests of differences in probable diagnostic rates for PTSD, CPTSD, and PTSD or CPTSD (N = 254).
PTSD CPTSD PTSD or CPTSD
Time 1: Pre-treatment 18.1% 52.8% 70.9%
Time 2: Mid-treatment 13.8% 22.0% 35.8%
Time 3: Post-treatment 11.0% 12.6% 23.6%
Overall test of significance (χ2)^ 6.50 (p = .039) 122.48 (p < .001) 145.634 (p < .001)
Pairwise tests of significance (Wald χ2)^^
Time 1 vs. Time 2 2.30 (p = .129) 94.99 (p < .001) 107.31 (p < .001)
Time 2 vs. Time 3 1.70 (p = .192) 14.50 (p < .001) 16.80 (p < .001)
Time 1 vs. Time 3 6.39 (p = .012) 155.19 (p < .001) 191.22 (p < .001)
^ tests have 2 degrees of freedom; ^^ tests have 1 degree of freedom. 
Note: PTSD = Posttraumatic Stress Disorder; CPTSD = Complex PTSD.
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(Shiner et al., 2011). Participants were distributed 
across all three categories within each of the symp-
tom scores where a substantial proportion fell into 
the improved group for PTSD symptoms (43.1%), 
DSO symptoms (54.0%) and CPTSD symptoms 
(56.1%). This result was similar to that for the 
PCL-5 where the greatest proportion of participants 
also fell into the ‘improved’ group (54.8%).
Reduction in scores surpassed the reliable change 
index identified for the PCL-5 and for the ITQ total 
score representing CPTSD. Reliable change was also 
observed for the ITQ DSO symptoms. Of note, the 
change observed for the ITQ PTSD symptoms was 
close to but did not exceed the RCI. While previous 
studies of STAIR and webSTAIR have been shown to 
provide significant reductions in DSM-5 PTSD, the 
reliability of symptom reduction was not evidenced 
in this analysis as it related to the ‘core’ symptoms 
represented in ICD-11 PTSD (re-experiencing, avoid-
ance, sense of threat). This result is likely a reflection 
of the treatment rather than the measure. It is quite 
possible that reliable reduction in these core PTSD 
symptoms is best obtained by interventions that have 
a trauma-focused component and the intervention 
that is part of this assessment did not.
WebSTAIR provides interventions that focus on 
problems in emotion regulation and social functioning 
and to a lesser extent, negative beliefs about oneself 
and others. All of these interventions directly address 
DSO symptoms and may be viewed to indirectly 
address PTSD symptoms. The greater improvements 
noted for the DSO and CPTSD scales are consistent 
with the proposed treatment targets of this interven-
tion. It is expected that STAIR or webSTAIR provided 
in conjunction with a trauma focused component, or 
indeed, other trauma-focused CBTS would provide 
larger and more reliable reductions in ICD-11 PTSD 
symptoms. The differences in the reliability of change 
observed between the DSO and PTSD subscales speaks 
to the potential value of the ITQ and ICD-11 diag-
noses in assessing differential effectiveness of treat-
ments regarding specific symptom clusters.
Tracking change with the ITQ may be useful in 
determining the relative advantages of a particular 
treatment for those with a PTSD versus a CPTSD 
diagnosis. It may also help refine and personalize 
treatments for those with CPTSD. The relative impor-
tance of the PTSD and DSO symptom clusters as well 
as their rate of change and relationship to each other 
across the course of treatment may differ depending 
on the CPTSD population (e.g. individuals who have 
experienced childhood maltreatment, interpersonal 
violence, torture, or life-threatening illnesses). 
Information regarding persistent versus rapidly chan-
ging symptoms or relative degree of co-occurring 
change can be used to flexibly adapt treatments, add, 
or eliminate treatment components, and thereby con-
tribute to the efficiency and effectiveness of treatment 
for CPTSD.
This study has some limitations that should be noted. 
The participants were U.S. Veterans therefore these find-
ings may not generalize to other clinical populations. 
There was considerable sample attrition – a common 
occurrence in clinical trials (Little et al., 2012) – and 
while the most robust methods of managing missing 
data were used, bias due to attrition cannot be entirely 
ruled out. The investigation lacked a control group and 
changes observed might have been due to factors other 
than the intervention. It is well established that chronic 
PTSD does not resolve over time (Kessler, 2000) and thus 
the passage of time is unlikely to have accounted for the 
observed change. However, a control group with 
a limited number of assessments would provide an eva-
luation of the effect of time as well as of repeated 
assessments.
Lastly, it should be noted that RCI values are rela-
tive to a specific treatment and study population and 
those obtained in this study may not generalize to 
other clinical samples and interventions. As noted by 
Jacobson and Truax (1991), it is recommended that 
clinically significant cut scores be standardized by 
aggregating results from various studies. Research is 
needed to identify RCI values for refugees, survivors of 
domestic violence, and childhood abuse survivors as 
well as for treatments which differ by interventions 
and targeted outcome (e.g. trauma-focused treat-
ments, mindfulness interventions).
In conclusion, this study is the first to offer evidence 
that the psychometric properties of the ITQ hold within 
a treatment context and that the ITQ captures reliable 
and clinically significant change related to treatment. 
The results of this study establish initial support for use 
of the ITQ in clinical trials and highlight the value of 
additional studies investigating reliable change in other 
trauma populations and treatments.
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